Platelet Suruival and Function in Rats with Enhanced Thrombotic Tendency

Summary

We have investigated the relevance of some laboratory tests of platelet function in predicting conditions of thrombotic tendency. For this purpose, we studied platelet survival, platelet aggregation in response to different stimuli, TxB2 and 6-keto-PGFlα production in serum of rats bearing a nephrotic syndrome induced by adriamycin. These animals show a heavy predisposition to the development of both arterial and venous thrombosis. The mean survival time was normal in nephrotic rats in comparison to controls. As to aggregation tests, a lower aggregating response was found in ADR-treated rats using ADP or collagen as stimulating agents. With arachidonic acid (AA) we observed similar aggregating responses at lower A A concentrations, whereas at higher AA concentrations a significantly lower response was found in nephrotic rats, despite their higher TxB2 production. Also TxB2 and 6-keto-PGFlα levels in serum of nephrotic rats were significantly higher than in controls. No consistent differences were found in PGI2-activity generated by vessels of control or nephrotic rats.

These data show that platelet function may appear normal or even impaired in rats with a markedly increased thrombotic tendency. On the other hand, the significance of high TxB2 levels in connection with mechanisms leading to thrombus formation remains a controversial issue.

Keywords

Thromboxane - Experimental thrombosis - Nephrotic syndrome

• References

• 1 Aharony D, Smith JB, Silver MJ. Regulation of arachidonate-induced platelet aggregation by the lipoxygenase product, 12-hyd-roperoxyeicosatetraenoic acid. Biochim Biophysi Acta 1982; 718: 193-200
• 2 Ardlie NG, Packham MA, Mustard JF. Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol 1970; 19: 07-17
• 3 Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G, Donati MB. Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982; 46: 16-23
• 4 Breddin K, Gross D, Rotter W. (eds.) Thrombosemodell am Tier. Prostaglandine und Thrombogenese; Schattauer, Stuttgart: 1981
• 5 Cattaneo M, Kinlough-Rathbone RL, Perry DW, Chahil A, Vickers JD, Lam SC-T, Packham MA, Mustard JF. The inhibitory effects of exogenous arachidonic acid on rabbit platelet aggregation and the release reaction. Blood 1982; 60: 1179-1187
• 6 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E₂ . Thromb Res 1982; 26: 389-400
• 7 de Gaetano G. Platelets, prostaglandins and thrombotic disorders. Clinics in Hematology. Vol. 10, n° 2. Thrombosis CR. M. Prentice (eds.) pp 297-326 Saunders; London: 1981
• 8 Dejana E, Cerletti C, de Castellarnau C, Livio M, Galletti F, Latini R, de Gaetano G. Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition. J Clin Invest 1981; 68: 1108-1112
• 9 Delaini F, Poggi A, Donati MB. Enhanced affinity for arachidonic acid in platelet-rich plasma from rats with adriamycin-induced nephrotic syndrome. Thromb Haemostas 1982; 48: 260-262
• 10 Delaini F, Reyers I, de Beilis Vitti G, Poggi A, Donati MB. Studies on a new model of thrombotic tendency in the rat. Thrombosemodell am Tier. Prostaglandine und Thrombogenese Breddin K, Gross D, Rotter W. (eds.) pp 147-155 Schattauer; Stuttgart: 1981
• 11 Folco G, Granstrom E, Kindahl H. Albumin stabilizes thromboxane A₂ . FEBS Letters 1977; 82: 321-324
• 12 Greenberg JP, Packham MA, Guccione MA, Rand ML, Reimers H-J, Mustard JF. Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin or neurominidase. Blood 1979; 53: 916-927
• 13 Hirsh J. Review: Blood tests for the diagnosis of venous and arterial thrombosis. Blood 1981; 57: 1-8
• 14 Hornstra G, Vendelmans-Starrenburg A. Induction of experimental arterial occulsive thrombi in rats. Atherosclerosis 1973; 17: 369-382
• 15 Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-314
• 16 Lewy RI, Smith JB, Silver MJ, Saia J, Walinsky P, Wiener L. Detection of thromboxane B₂ in peripheral blood of patients with Prinzmetal’s angina. Prostaglandins Med 1979; 5: 243-248
• 17 Murphy EA, Bolling DR. Platelet survival. Platelet Function Testing. Day HJ, Hahnson H, Zucker MB. (eds.) pp 561-567 NIH Publication No. 78-1087 1978
• 18 Packham MA, Warrior ES, Glynn MF, Senyi AS, Mustard JF. Alteration of the response of platelets to surface stimuli by pyrazole compounds. J Exp Med 1967; 126: 171-188
• 19 Poggi A, Kornblihtt L, Delaini F, Colombo T, Mussoni L, Reyers I, Donati MB. Delayed hypercoagulability after a single dose of adriamycin to normal rats. Thromb Res 1979; 16: 639-650
• 20 Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-674
• 21 Roncaglioni MC, Bertele V, de Gaetano G, Donati MB. Lack of interaction of heparin with ADP and prostacyclin on rat platelets. Thromb Res 1983; 31: 397-400
• 22 Roncaglioni MC, di Minno G, Pangrazzi J, Reyers I, Mussoni L, de Gaetano G, Donati MB. Plasmatic and vascular factors of the hemostatic system in rats receiving an estrogen-progestogen combination. Contraception 1980; 22: 249-257
• 23 Winocour PD, Cattaneo M, Somers D, Richardson M, Kinlough-Rathbone RL, Mustard JF. Platelet survival and thrombosis. Arteriosclerosis 1982; 2: 458-466